Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2014. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) or their connected persons, specifically regarding the sale of shares to meet tax liabilities.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on specific share transaction details:
- Ordinary Shares Sale Price: £16.73 per share.
- American Depositary Shares (ADS) Withholding Price: $55.69 per ADS.
- Transaction Date: February 24, 2014.
Material Changes
The filing reports specific changes in shareholdings for connected persons of PDMRs resulting from the vesting of awards granted in 2011 under the GlaxoSmithKline 2009 Share Value Plan (SVP):
- Mr. P. Thomson: Connected person Mrs. K. Thomson sold 1,039 Ordinary Shares to meet tax liabilities.
- Dr. M. Slaoui (Executive Director): Connected person Mrs. K. Slaoui had 876 ADSs withheld to meet tax liabilities.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of unusual items. It is a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Points
- Verify the total number of shares sold or withheld by connected persons of PDMRs during the reporting period.
- Confirm the fair market value prices used for the transactions (£16.73 for Ordinary Shares and $55.69 for ADSs).
- Ensure the transactions were properly notified to the company on February 25, 2014, as stated in the filing.